Inozyme Pharma Stock Current Valuation

INZY Stock  USD 1.46  0.04  2.82%   
Valuation analysis of Inozyme Pharma helps investors to measure Inozyme Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -2.94 in 2025. Enterprise Value Multiple is likely to drop to -2.94 in 2025. Fundamental drivers impacting Inozyme Pharma's valuation include:
Price Book
1.1329
Enterprise Value
M
Enterprise Value Ebitda
(4.25)
Undervalued
Today
1.46
Please note that Inozyme Pharma's price fluctuation is unstable at this time. Calculation of the real value of Inozyme Pharma is based on 3 months time horizon. Increasing Inozyme Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Inozyme Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inozyme Stock. However, Inozyme Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.46 Real  6.15 Target  20.25 Hype  1.52 Naive  2.03
The intrinsic value of Inozyme Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inozyme Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
6.15
Real Value
12.36
Upside
Estimating the potential upside or downside of Inozyme Pharma helps investors to forecast how Inozyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inozyme Pharma more accurately as focusing exclusively on Inozyme Pharma's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.42-0.38-0.33
Details
Hype
Prediction
LowEstimatedHigh
0.081.527.73
Details
Naive
Forecast
LowNext ValueHigh
0.042.038.24
Details
9 Analysts
Consensus
LowTarget PriceHigh
18.4320.2522.48
Details

Inozyme Pharma Company Current Valuation Analysis

Inozyme Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Inozyme Pharma Current Valuation

    
  8.97 M  
Most of Inozyme Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Inozyme Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Inozyme Pharma is extremely important. It helps to project a fair market value of Inozyme Stock properly, considering its historical fundamentals such as Current Valuation. Since Inozyme Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inozyme Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inozyme Pharma's interrelated accounts and indicators.
0.970.940.15-0.910.590.830.940.93-0.480.870.941.01.00.850.780.830.670.79-0.42
0.971.00.01-0.870.760.720.910.94-0.680.850.940.960.950.770.870.810.720.64-0.36
0.941.0-0.06-0.840.810.660.880.92-0.730.840.920.930.920.710.880.780.720.56-0.32
0.150.01-0.06-0.45-0.40.440.250.260.350.110.20.190.190.520.030.530.460.56-0.44
-0.91-0.87-0.84-0.45-0.5-0.88-0.95-0.960.41-0.81-0.94-0.92-0.91-0.95-0.73-0.92-0.84-0.80.57
0.590.760.81-0.4-0.50.290.610.69-0.950.620.660.550.540.360.810.450.610.02-0.21
0.830.720.660.44-0.880.290.930.84-0.160.690.890.840.840.970.510.680.540.91-0.78
0.940.910.880.25-0.950.610.930.97-0.510.820.990.930.930.940.770.790.720.79-0.68
0.930.940.920.26-0.960.690.840.97-0.610.840.980.920.920.910.830.870.840.7-0.6
-0.48-0.68-0.730.350.41-0.95-0.16-0.51-0.61-0.42-0.58-0.44-0.43-0.27-0.78-0.42-0.610.060.18
0.870.850.840.11-0.810.620.690.820.84-0.420.80.860.860.690.790.780.70.59-0.34
0.940.940.920.2-0.940.660.890.990.98-0.580.80.940.930.910.80.80.740.75-0.64
1.00.960.930.19-0.920.550.840.930.92-0.440.860.941.00.860.760.840.670.82-0.43
1.00.950.920.19-0.910.540.840.930.92-0.430.860.931.00.860.750.830.650.83-0.43
0.850.770.710.52-0.950.360.970.940.91-0.270.690.910.860.860.570.80.710.88-0.76
0.780.870.880.03-0.730.810.510.770.83-0.780.790.80.760.750.570.780.790.38-0.3
0.830.810.780.53-0.920.450.680.790.87-0.420.780.80.840.830.80.780.920.69-0.37
0.670.720.720.46-0.840.610.540.720.84-0.610.70.740.670.650.710.790.920.43-0.42
0.790.640.560.56-0.80.020.910.790.70.060.590.750.820.830.880.380.690.43-0.57
-0.42-0.36-0.32-0.440.57-0.21-0.78-0.68-0.60.18-0.34-0.64-0.43-0.43-0.76-0.3-0.37-0.42-0.57
Click cells to compare fundamentals

Inozyme Current Valuation Historical Pattern

Today, most investors in Inozyme Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inozyme Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Inozyme Pharma current valuation as a starting point in their analysis.
   Inozyme Pharma Current Valuation   
       Timeline  
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Inozyme Pharma has a Current Valuation of 8.97 M. This is 99.94% lower than that of the Biotechnology sector and 99.81% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.95% higher than that of the company.

Inozyme Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.
Inozyme Pharma is currently under evaluation in current valuation category among its peers.

Inozyme Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inozyme Pharma from analyzing Inozyme Pharma's financial statements. These drivers represent accounts that assess Inozyme Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inozyme Pharma's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap482.7M160.7M39.7M220.8M254.0M263.1M
Enterprise Value324.1M140.7M13.5M232.8M267.8M215.4M

Inozyme Fundamentals

About Inozyme Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.